Annexon to Participate in Upcoming June Investor Conferences
Annexon (Nasdaq: ANNX) announced that president and CEO Douglas Love will join fireside chats at two June 2026 investor conferences.
Rhea-AI Summary
Annexon (Nasdaq: ANNX) announced that president and CEO Douglas Love will join fireside chats at two June 2026 investor conferences.
He will appear at the Jefferies Global Healthcare Conference on June 3, 2026 at 11:40 a.m. ET in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 at 8:00 a.m. ET in Miami Beach. Live webcasts and 30-day replays will be available in the Events & Presentations section of Annexon’s investor website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ANNX
On May 27, the day this news came out, ANNX closed 2.36% below the previous close.
Data tracked by StockTitan Argus for the May 27 session.
Key Figures
- Disease burden
- nearly 10 million people
- Neuroinflammatory diseases impacted by Annexon’s targeted immunotherapies
- Jefferies conference date
- June 3, 2026
- Jefferies Global Healthcare Conference fireside chat
- Jefferies time
- 11:40 a.m. ET
- Scheduled time for Jefferies Global Healthcare fireside chat
- Goldman Sachs conference date
- June 9, 2026
- Goldman Sachs 47th Annual Global Healthcare Conference fireside chat
- Goldman Sachs time
- 8:00 a.m. ET
- Scheduled time for Goldman Sachs conference appearance
- Conference edition
- 47th Annual
- Goldman Sachs Annual Global Healthcare Conference
- Webcast archive period
- 30 days
- Length of time replays remain available on Annexon’s website
Historical Context
-
Equity inducement option grants under Nasdaq Listing Rule 5635(c)(4).
-
Quarterly results, cash of $225.0 million and 2026 pipeline milestones.
-
Presentation at Bank of America Securities Health Care Conference 2026.
-
Needham Virtual Healthcare Conference presentation and webcast availability.
-
Full-year 2025 results, cash $238.3 million and 2026 milestones.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
immunotherapies medical
neuroinflammatory medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:
- Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
- Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET in Miami Beach, FL.
Live webcasts of the presentations can be accessed under the ‘Events & Presentations’ section on the Investors page at annexonbio.com. Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.